|By Marketwired .||
|June 30, 2014 04:15 PM EDT||
NEW YORK, NY -- (Marketwired) -- 06/30/14 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased OvaScience, Inc. ("OvaScience" or the "Company") (NASDAQ: OVAS) securities between February 25, 2013 and September 10, 2013.
For more information, click here: http://zlk.9nl.com/ovascience.
The complaint alleges that defendants made materially false and misleading statements regarding the Company's business and operations. In particular, OvaScience represented to investors and the Food and Drug Administration that its fertility treatment AUGMENT would likely qualify for designation as a 361 HCT/P, which allows human cellular and tissue based products to be tested and marketed without FDA licensure.
On September 10, 2013, the Company disclosed the receipt of a letter from the FDA in which the status of AUGMENT as a 361 HCT/P was questioned. The FDA also requested that OvaScience file an Investigational New Drug (IND) application, thus ensuring that the drug face mandatory clinical testing.
If you suffered a loss in OvaScience you have until August 5, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ovascience.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Jul. 30, 2016 01:00 PM EDT Reads: 1,850
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Jul. 30, 2016 01:00 PM EDT Reads: 2,116
Jul. 30, 2016 12:00 PM EDT Reads: 1,341
Jul. 30, 2016 11:30 AM EDT Reads: 1,375
Jul. 30, 2016 11:00 AM EDT Reads: 529
Jul. 30, 2016 11:00 AM EDT Reads: 621
Jul. 30, 2016 10:45 AM EDT Reads: 1,063
Jul. 30, 2016 10:15 AM EDT Reads: 1,038
Jul. 30, 2016 10:15 AM EDT Reads: 1,507
Jul. 30, 2016 10:00 AM EDT Reads: 522
Jul. 30, 2016 10:00 AM EDT Reads: 2,178
Jul. 30, 2016 09:45 AM EDT Reads: 517
Jul. 30, 2016 09:30 AM EDT Reads: 823
Jul. 30, 2016 09:30 AM EDT Reads: 808
Jul. 30, 2016 09:15 AM EDT Reads: 1,656